Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v21-FR Version v7-EN
Language French English
Date Updated 2020-07-30 2020-03-23
Drug Identification Number 02326450 02326450
Brand name TEVA-SALBUTAMOL HFA TEVA-SALBUTAMOL HFA
Common or Proper name SALBUTAMOL 100MCG HFA INHALER SALBUTAMOL 100MCG HFA INHALER
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients SALBUTAMOL SALBUTAMOL
Strength(s) 100MCG 100MCG
Dosage form(s) METERED-DOSE AEROSOL METERED-DOSE AEROSOL
Route of administration INHALATION INHALATION
Packaging size 200 dose 200 dose
ATC code R03AC R03AC
ATC description ADRENERGICS, INHALANTS ADRENERGICS, INHALANTS
Reason for shortage Other (Please describe in comments) Delay in shipping of the drug.
Anticipated start date
Actual start date 2020-02-07 2020-02-07
Estimated end date 2020-07-31 2020-04-30
Actual end date 2020-07-29
Shortage status Resolved Actual shortage
Company comments Teva Allocating to 70% of the generic market. Increased demand experienced. Teva Allocating to 70% of the market. Increased demand experienced.
Health Canada comments